(The use of Phosphodiesterase 5 Inhibitors (PDE-5-Is) alone or in Combination with Alpha-blockers for Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH

Abstract

ower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) are common conditions in middle-age or older men. LUTS range from mild to severe, and include obstructive symptoms such as hesitancy, incomplete emptying, and weak stream, and irritative symptoms such as frequency, urgency, and nocturia, that can strongly worsen the quality of life (QoL). For several years, surgery has represented the gold standard of care for this condition, allowing the relief of urinary symptoms and the consequent improvement in QoL. Several randomized controlled trials (RCTs) on phosphodiesterase type 5 inhibitors (PDE-5-Is) have showed significant improvements in both (LUTS) and (ED) in men affected by one or both conditions, without a significant increase in adverse events. The study was performed to determine the relative efficacy and safety of PDE5-Is alone or in combination with alpha-1 adrenergic blockers in LUTS due to BPH. Our study was conducted on 60 patients diagnosed with LUTS/BPH and ED presented at Ain shams university hospital.